The 3 most recent market catalysts affecting $EOS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 65
Eos SENOLYTIX Announces New Preclinical Data for PTC-2105
Eos SENOLYTIX, a company in a pending merger with Pulmatrix, reported new preclinical data for its lead product candidate, PTC-2105. The data indicates that PTC-2105 successfully r…
Oct 22, 2026
Corporate Catalyst
Neutral
Impact 65
Eos SENOLYTIX Presents Preclinical Data for PTC-2105 at World Congress on Targeting Mitochondria
Eos SENOLYTIX, the private company set to merge with Pulmatrix, presented new preclinical data for its lead drug candidate, PTC-2105, at a major scientific conference. This is sign…
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 55
Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4
Eos SENOLYTIX is announcing its CEO will deliver a keynote address at the 17th World Congress on Targeting Mitochondria in October 2026, showcasing its mitochondrial-targeted gerot…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.